Laxman Hanmantrao Malge
About Laxman Hanmantrao Malge
Data last updated:
Laxman Hanmantrao Malge has 15 years in corporate governance. Holds Director role. Currently with 1 company, including Florentis Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Florentis Pharmaceuticals Private Limited at ₹1.55 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Florentis Pharmaceuticals Private Limited U24100PN2011PTC140877 | Director | 26 Sep 2011 | 2011 | ₹1.55 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Laxman Hanmantrao Malge
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laxman Hanmantrao Malge
Laxman Hanmantrao Malge has 15 years in corporate governance. Holds Director role. Currently with 1 company, including Florentis Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Florentis Pharmaceuticals Private Limited at ₹1.55 Cr (FY 2025).
Laxman Hanmantrao Malge is associated with 1 company as Director, including Florentis Pharmaceuticals Private Limited (₹1.55 Cr).
Laxman Hanmantrao Malge has expertise in General Business.
Laxman Hanmantrao Malge has 15 years in corporate governance.
By reported revenue, the largest current company of Laxman Hanmantrao Malge is Florentis Pharmaceuticals Private Limited, with revenue of ₹1.55 Cr (FY 2025).
Laxman Hanmantrao Malge currently holds positions at 1 company: Florentis Pharmaceuticals Private Limited (₹1.55 Cr).